Nuevolution A/S today announced that it has entered into a lead discovery collaboration focused on epigenetic disorders.
A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors. The 24 MDKK budget project is supported by the Danish High Technology Fund.
Showing posts with label Nuevolution A/S. Show all posts
Showing posts with label Nuevolution A/S. Show all posts
Wednesday, 6 October 2010
Subscribe to:
Posts (Atom)